

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 December 2004 (29.12.2004)

PCT

(10) International Publication Number
WO 2004/113269 A1

(51) International Patent Classification⁷: C07C 227/00

(21) International Application Number:
PCT/EP2004/006513

(22) International Filing Date: 17 June 2004 (17.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
MI2003A001247 20 June 2003 (20.06.2003) IT

(71) Applicant (for all designated States except US): ZAMBON GROUP SPA [IT/IT]; Via della Chimica 9, I-36100 Vicenza (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COTARCA, Livius [RO/IT]; Via Mercato 18, I-33052 Cervignano del Friuli (UD) (IT). GIOVANETTI, Roberto [IT/IT]; via L. Da Vinci 121, I-36015 Schio (VI) (IT). NICOLI, Andrea [IT/IT]; via Monzanbano 50, I-36100 Vicenza (IT).

(74) Agent: LONGONI, Alessandra; ZAMBON GROUP S.p.A., Intellectual Property Dept., Via Lillo del Duca 10, I-20091 Bresso (MI) (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PURIFICATION OF GABAPENTIN

(57) Abstract: A process for the preparation of gabapentin which comprises the passage of a gabapentin inorganic salt through a strong cationic ionic exchange resin, the elution of gabapentin fixed on the column, the concentration of the resultant solution and the crystallization from organic solvent, characterized in that the elution of gabapentin fixed on the column is carried out by using an ammonia and alkaline hydroxide aqueous solution, is described.

WO 2004/113269 A1

"PROCESS FOR THE PURIFICATION OF GABAPENTIN"

The present invention relates to a process for the preparation of gabapentin.

- 5 Gabapentin (The Merck Index XII Ed., page 733, No. 4343) is a known drug endowed with anti-epileptic activity described for the first time by Warner Lambert Co. in the US patent 4,024,175.

In the literature several processes for the preparation of gabapentin are reported (see for example the US patents 4,024,175, 5,068,413 and 5,091,567).

- 10 Substantially, all these methods foresee a final step of purification by column chromatography of an aqueous solution of a gabapentin salt, generally hydrochloride, through a weak basic ionic exchange resin.

- In the patent application PCT No. WO 02/34709 in the name of the same Applicant, a process of purification that foresees the chromatography of an aqueous solution of
15 gabapentin hydrochloride through strong cationic ionic exchange resins is described.

The process described in the above cited PCT patent application is very efficient and it allows to obtain, after concentration of the eluate and crystallization, a high pure product, almost completely free from the corresponding lactam which is a substance endowed with a certain toxicity (Von A. Enders et al., Arzneimittel Forschung, 10, (1960), 243-250).

- 20 During the chromatographic phase on cationic resin, gabapentin is fixed to the resin allowing the other substances to percolate, in particular organic impurities coming from the synthetic process.

Gabapentin is then eluted with an ammonia aqueous solution with a concentration around 3-4% and then with water.

- 25 The fractions containing gabapentin are collected and concentrated under vacuum till obtaining a solid residue from which gabapentin is isolated by crystallization from organic solvents, preferably alcoholic solvents.

The above described process itself appears [to be] optimum with regard to the purification of gabapentin.

- 30 Nevertheless, said process needs a high amount of ammonia solution (about 4500 liters at 3% for 350 Kg of gabapentin). The ammonia solution must then be drained by a biological

- 2 -

draining system and this results both in an increase in costs and in a prolonged utilization of the draining system itself.

We have now found a variation to the process described in the patent application PCT No. 5 WO 02/34709 which allows to considerably reduce the amount of the used ammonia solution obtaining at the same time an equally pure product and with substantially the same yields. Said variation consists in eluting gabapentin fixed on the strong cationic resin with an ammonia and alkaline hydroxyde aqueous solution.

Therefore, object of the present invention is a process for the preparation of gabapentin 10 which comprises the passage of a gabapentin inorganic salt through a strong cationic ionic exchange resin, the elution of gabapentin fixed on the column, the concentration of the resultant solution and the crystallization from organic solvent, characterized by the fact that the elution of gabapentin fixed on the column is carried out by using an ammonia and alkaline hydroxide aqueous solution.

15 Preferably, for economic reasons purely, the alkaline hydroxide is sodium hydroxide.

Not limitative examples of strong cationic resins useful in the process of the invention are IRA120, DIAION SK1B and IMAC HP1110.

The amount of alkaline hydroxide must not exceed the molar amount of cationic resin used in order to minimize the amount of alkaline hydroxide which elutes with gabapentin forming 20 an alkaline salt of gabapentin.

Preferably, the concentration of NH_3 in the elution solutions is around 3-4% by weight and the concentration of NaOH around 7% by weight. The ratio between NH_3 and NaOH is preferably from 1:1 to 1:2.

At the end of elution the column is washed with demineralised water.

25 Practically, the method object of the invention allows to substitute a relevant amount (about 60-70%) of ammonia with sodium hydroxide and this results in a significant reduction of draining time and costs of the ammonia solution.

As further collateral advantage, the eluate volume is reduced of about 20% with further reduction of costs and time.

30 Thus, for example, if 4500 l of an aqueous solution of NH_3 at 3% every 350 Kg of

- 3 -

gabapentin by the method described in the patent application PCT No. WO 02/34709 were necessary, 4100 l of an aqueous solution of NH_3 at 3% (1400 l) and a solution of NaOH at 7% (2700 l) for the same amount of gabapentin by the method object of the present invention
5 are sufficient.

The eluate also contains a small amount of alkaline hydroxide in the form of gabapentin salt, for example sodium salt, which may possess a destabilizing effect on gabapentin.

Nevertheless, the elimination of the sodium salt can be realized by adding a small amount of mineral acid to the solution, preferably HCl.

10 HCl (a diluted aqueous solution) can be directly added in the eluate or after having concentrated it at about 50% by distillation i.e after having substantially removed the ammonia.

The subsequent crystallization according to known techniques removes a great part of the chlorides added, giving gabapentin containing chlorides between 30 and 70 ppm i.e. in line
15 with pharmacopoeia requirements (less than 100 ppm).

In a practical embodiment the process of the invention comprises fixing gabapentin on a strong cationic resin, washing with water in order to remove the inorganic acid, eluting the resin with an ammonia and sodium hydroxide aqueous solution and washing the resin with demineralised water, collecting the fractions containing gabapentin, concentrating the
20 solution till about 50%, neutralizing the present sodium salt of gabapentin with HCl, further concentrating till obtaining a thick residue, crystallizing gabapentin from alcoholic solvents.

For better illustrating the present invention the following examples are now given.

Example 1

In a glass column (diameter 45 mm, height 450 mm) endowed with porous septum, 500 ml
25 of suitably activated and regenerated resin Diaion SK1B were charged.

A solution of gabapentin hydrochloride (652 g of solution at 14.48% equal to 94.4 g of gabapentin) was eluted through the column.

The column was then washed eluting with demineralised water about 1500 g till pH 7.

Then, a mixture (720 g) of an ammonia solution at 3% (240 g) and a solution of NaOH at 7%
30 (480 g) was eluted through the column.

- 4 -

At the end the column was eluted with demineralised water till pH 7 (about 1500 g).

The fractions of eluate containing gabapentin were collected obtaining a solution (2171 g) containing gabapentin (4.25%, 92.3 g).

- 5 To the solution, 23.4 g of HCl solution at 3.99% (equal to 0.934 g of HCl) was added.

The solution was then concentrated under vacuum at a temperature below 40°C obtaining a crude (91.2 g) containing gabapentin at 97.6%.

In a 500 ml reactor under nitrogen crude gabapentin (70 g), demineralised water (34.7 g) and methanol (43.7 g) were charged.

- 10 The suspension was heated at 50°C for 30 minutes and then isopropyl alcohol (180.5 g) was added dropwise in 30 minutes.

The mixture was kept at 50°C for further 30 minutes and then it was cooled at 25°C in 2 hours and at -5°C in a further hour, keeping this temperature for further 2 hours.

The solid was filtered and washed on the filter with isopropyl alcohol cooled at -5°C.

- 15 After drying in oven at 45°C, gabapentin (64 g) was obtained with purity higher than 99%, lactam under 0.01% and 69 ppm of chlorides (expressed as Cl⁻).

- 5 -

Claims

- 1) A process for the preparation of gabapentin which comprises the passage of a gabapentin inorganic salt through a strong cationic ionic exchange resin, the elution of gabapentin fixed
5 on the column, the concentration of the resultant solution and the cristallization from organic solvent, characterized in that the elution of gabapentin fixed on the column is carried out by using an ammonia and alkaline hydroxide aqueous solution.
- 2) A process according to claim 1 wherein the alkaline hydroxide is NaOH.
- 3) A process according to claim 1 wherein the ammonia and NaOH aqueous solution is
10 obtained by mixing an ammonia aqueous solution at 3-4% with a sodium hydroxide aqueous solution at 7-8%.
- 4) A process according to claim 1 wherein the gabapentin sodium salt that is present in the eluate is neutralized with an aqueous solution of HCl.
- 5) A process according to claim 1 which comprises fixing gabapentin on a strong cationic
15 resin, washing with water, eluting the resin with an ammonia and sodium hydroxide aqueous solution and washing the resin with demineralised water, collecting the fractions containing gabapentin, concentrating the solution till about 50%, neutralizing by HCl the present gabapentin sodium salt, further concentrating till a thick residue, crystallizing gabapentin from alcoholic solvents.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference C-392	FOR FURTHER ACTION <small>see Form PCT/ISA/220 as well as, where applicable, item 5 below.</small>	
International application No. PCT/EP2004/006513	International filing date (day/month/year) 17/06/2004	(Earliest) Priority Date (day/month/year) 20/06/2003
Applicant ZAMBON GROUP SPA		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, see Box No. I.

2. ☐ Certain claims were found unsearchable (See Box II).

3. ☐ Unity of invention is lacking (see Box III).

4. With regard to the title,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regards to the drawings,

a. the figure of the drawings to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ as selected by this Authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.

b. ☒ none of the figures is to be published with the abstract.

INTERNATIONAL SEARCH REPORT

International Application No

PO/EP2004/006513

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07C227/40 C07C227/42 C07C229/28		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07C		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/34709 A (NICOLI ANDREA ; ZAMBON SPA (IT); CANNATA VINCENZO (IT); CORCELLA FRANC) 2 May 2002 (2002-05-02) the whole document	1-5
Y	DYE S R ET AL: "EQUILIBRIUM SORPTION OF AMINO ACIDS BY A CATION-EXCHANGE RESIN" INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 29, no. 5, 1 May 1990 (1990-05-01), pages 849-857, XP000165650 ISSN: 0888-5885 *page 849, left-hand column, paragraph 1-right-hand column, paragraph 1, experimental section, page 850* ----- -/-	1-5
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 10 September 2004		Date of mailing of the international search report 07/12/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Lorenzo Varela, M.J.

3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/006513

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim-No.
Y	EP 0 414 263 A (GOEDECKE AG) 27 February 1991 (1991-02-27) example 2	1-5
Y	WO 00/01660 A (ARRIGHI KATIUSCIA ; PAIOCCHI MAURIZIO (IT); RUSSO LAURA (IT); VILLA MA) 13 January 2000 (2000-01-13) *the whole document; in particular, page 3, lines 8-11 and the examples*	1-5

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/006513

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0234709	A	02-05-2002	IT MI20002285 A1	23-04-2002
			CA 2425615 A1	02-05-2002
			DE 10196805 T0	15-04-2004
			WO 0234709 A1	02-05-2002
			EP 1341749 A1	10-09-2003
			ES 2206078 A1	01-05-2004
			GB 2383041 A	18-06-2003
			HU 0302602 A2	28-11-2003
			JP 2004512321 T	22-04-2004
			US 2004068011 A1	08-04-2004
EP 0414263	A	27-02-1991	DE 3928183 A1	28-02-1991
			AT 113272 T	15-11-1994
			DE 59007550 D1	01-12-1994
			DK 414263 T3	16-01-1995
			EP 0414263 A2	27-02-1991
			ES 2063219 T3	01-01-1995
			HK 1003480 A1	30-10-1998
			IE 903089 A1	27-02-1991
			JP 3090053 A	16-04-1991
			JP 3148223 B2	19-03-2001
			JP 2001058976 A	06-03-2001
			PT 95082 A ,B	18-04-1991
			US 6054482 A	25-04-2000
WO 0001660	A	13-01-2000	IT MI981535 A1	03-01-2000
			WO 0001660 A1	13-01-2000
			EP 1095010 A1	02-05-2001